Pubdate: Tue, 26 Jan 2016
Source: Philadelphia Inquirer, The (PA)
Copyright: 2016 Philadelphia Newspapers Inc
Author: Scott E. Shapiro


The U.S. Drug Enforcement Administration's decision last month to 
relax requirements for marijuana-derived research is encouraging. The 
Pennsylvania Medical Society, on behalf of our members and their 
patients, urges that the U.S. Food and Drug Administration also work 
to support research that will lead to the development of safe 
treatment options.

We also urge the FDA to reschedule marijuana from a Schedule I to a 
Schedule II substance to facilitate research across the country.

With legislation to legalize medical marijuana pending in 
Pennsylvania, we are hopeful that the DEA decision will slow down 
state legislation on marijuana legalization in favor of FDA-approved 
clinical research and rescheduling of the substance. Advocates and 
patients want to use marijuana for illnesses and conditions despite 
incomplete and limited FDA research on its safety and effectiveness. 
Society members prefer additional research and clinical study before 
Pennsylvania allows medical use of marijuana. This position is 
aligned with the American Medical Association's policy.

Dr. Scott E. Shapiro, president, Pennsylvania Medical Society,

- ---
MAP posted-by: Jay Bergstrom